Latest News

First anticoagulant approved for preventing VTE recurrence in children

(HealthDay)—Fragmin (dalteparin sodium) injection has been granted the first approval for subcutaneous use in preventing recurrence of symptomatic venous thromboembolism (VTE) in children aged 1 month or older, the U.S. Food and Drug Administration announced.

Source link

Related posts

Researchers unravel the biology of how obesity promotes triple-negative breast cancer


Liquid biopsy has prognostic role in colorectal cancer and potential for guiding therapy


Surgeons report on rural preparedness response plan for dealing with COVID-19


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy